Joint Formulary & PAD

Finerenone - Chronic Kidney Disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

Primary Care prescribing may be suitable following initiation by a specialist renal centre, locally those centres are Epsom & St Helier, Frimley or Brighton hospitals.

PAD Profile

ChemicalSubstance :
Finerenone
Indication :
Chronic Kidney Disease
Group Name :
Keywords :
CKD
Brand Names Include :
Kerendia
Important Information :

Stage 3 and 4, associated with Type 2 diabetes as per NICE TA877

Specialist teams should prescribe for at least 12 weeks to enable appropriate dose titrations and stabilisation of treatment prior to transfer of care.

Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
3

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status for finerenone for chronic kidney disease (CKD) associated with Type 2 Diabetes.

Finerenone for this indication will be given a BLUE (with specialist team initiation) traffic light status. Specialist teams should prescribe for at least 12 weeks to enable appropriate dose titrations and stabilisation of treatment prior to transfer of care.

Primary Care prescribing may be suitable following initiation by a specialist renal centre, locally those centres are Epsom & St Helier, Frimley or Brighton.

Other Indications

Below are listed other indications that Finerenone is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic Kidney Disease.